



Universiteit
Leiden
The Netherlands

Innovation in cholinergic enhancement for Alzheimer's Disease

Baakman, A.C.

Citation

Baakman, A. C. (2021, November 17). *Innovation in cholinergic enhancement for Alzheimer's Disease*. Retrieved from <https://hdl.handle.net/1887/3240157>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3240157>

Note: To cite this publication please use the final published version (if applicable).





Innovation in cholinergic enhancement in Alzheimer's Disease

PROEFSCHRIFT

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op woensdag 17 november 2021
klokke 11.15 uur

DOOR

Annechiena Catharina Baakman
geboren te Vollenhove in 1983

PROMOTORES

Prof. dr. J.M.A. van Gerven

Prof. dr. P. Scheltens

Prof. dr. G.J. Groeneveld

LEDEN PROMOTIECOMMISSIE

Prof. dr. O.C. Meijer

Prof. dr. W.M. van der Flier (Amsterdam UMC)

Prof. dr. G.J. Blauw

Dr. A.W. Lemstra (Amsterdam UMC)

COVER

Geertje Piësla-Roodbol, Amsterdam

DESIGN

Caroline de Lint, Voorburg (caro@delint.nl)

All rights reserved. No part from this thesis may be reproduced, distributed or transmitted in any form or by any means, without prior written permission of the author.

Publication of this thesis was financially supported by the foundation Centre for Human Drug Research, Leiden, the Netherlands.

7 Introduction

21 Chapter 2

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

37 Chapter 3

An anti-nicotinic cognitive challenge model using mecamlamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

57 Chapter 4

Pharmacokinetics and pharmacodynamics of oral mecamlamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.

81 Chapter 5

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

97 Chapter 6

Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's Disease.

121 Chapter 7

Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

147 Chapter 8

Discussion

157 Dutch summary

165 Curriculum Vitae

167 List of publications

